UCLA's Jonsson Comprehensive Cancer Center : JCCC Member Directory

Bartosz Chmielowski, M.D.

Specialty:

Hematology and Oncology

General Information:

Gender:	Male
Language(s):	English, Polish

Affiliation(s):

Clinical Assistant Professor, Department of Medicine, Hematology/Oncology

Member, JCCC Signal Transduction and Therapeutics Program Area

Hospital Affiliation(s):

Ronald Reagan UCLA Medical Center

Santa Monica-UCLA Medical Center and Orthopaedic Hospital

Education:

Fellowship:	Hematology-Oncology, UCLA School of Medicine, 2005 - 2008
Residency:	Internal Medicine, Medical College of Georgia Hospital, 2002 - 2005
Internship:	Internal Medicine, Medical College of Georgia Hospital, 2001 - 2002
Medical Degree:	M.D., Akademia Medyczna W Wroclawiu, 1995

Certification(s):

Medical Board Certification(s):	Medical Oncology, American Board of Internal Medicine, 2008 Hematology, American Board of Internal Medicine, 2008 Internal Medicine, American Board of Internal Medicine, 2004

Contact Information:

Phone:	(310) 794-4955 Westwood (310) 829-5471 Santa Monica
Email:	bchmielowski@mednet.ucla.edu

Practice Information:

Clinical Interest(s):	Melanoma Sarcoma

Scientific Interest(s):

Dr. Bartosz Chmielowski’s research concentrates mainly on the end-part of translational projects, when the laboratory research is already studied in the clinical setting. He is interested in phase 1, phase 2 and phase 3 clinical trials in patients with melanoma and sarcoma.

Selected Cancer-Related Publications:

Søndergaard JN, Nazarian R, Wang Q, Guo D, Hsueh T, Mok S, Sazegar H, MacConaill LE, Barretina JG, Kehoe SM, Attar N, von Euw E, Zuckerman JE, Chmielowski B, Comin-Anduix B, Koya RC, Mischel PS, Lo RS, Ribas A. Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. J Transl Med. 2010 Apr 20;8:39.

Ribas A, Comin-Anduix B, Chmielowski B, Jalil J, de la Rocha P, McCannel TA, Ochoa MT, Seja E, Villanueva A, Oseguera DK, Straatsma BR, Cochran AJ, Glaspy JA, Hui L, Marincola FM, Wang E, Economou JS, Gomez-Navarro J. Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res. 2009 Oct 1;15(19):6267-76. Epub 2009 Sep 29.

Chmielowski B, Pacholczyk R, Kraj P, Kisielow P, Ignatowicz L. Presentation of antagonist peptides to naïve CD4+ T cells abrogates spatial reorganization of class II MHC peptide complexes on the surface of dendritic cells. Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):15012-7. Epub 2002 Oct 31.

Gaszewska-Mastalarz A, Muranski P, Chmielowski B, Kraj P, Ignatowicz L. Altered selection of CD4+ T cells by class II MHC bound with dominant and low abundance self-peptides. J Immunol. 2000 Dec 1;165(11):6099-106.

Chmielowski B, Muranski P, Kisielow P, Ignatowicz L. On the role of high- and low-abundance class II MHC-peptide complexes in the thymic positive selection of CD4(+) T cells. Int Immunol. 2000 Jan;12(1):67-72.